SMab from Yurogen for distributor


Introduction of SMab TM Platform
Affinibody is proud to announce our new single B cell-based monoclonal antibody (SMab TM ) platform
to develop monoclonal antibodies (mAbs) from various species especially from rabbit. SMab TM platform
is automation-facilitated highthroughput platform which means Affinibody can expediate delivery of
superior mAbs to our customers in less then 4.5 months starting from animal immunization. It is a robust
platform that has successfully complete 150+ CRO rabbit mAb projects, yielding high affinity mAbs with
broad diversity.